Impact de la personnalité sur l'intensité du syndrome de sevrage alcoolique : une étude préliminaire avec le modèle de Cloninger.
; Pinto, Emmanuel ; Reggers, Jean et al
in Encéphale (L') (2007), 33Detailed reference viewed: 71 (5 ULg)
Syndrome de discontinuation associé aux antidépresseurs.
Pitchot, William ; Scantamburlo, Gabrielle ; Pinto, Emmanuel et al
in Revue Médicale de Liège (2007), 62Detailed reference viewed: 69 (6 ULg)
Nouveautés dans le traitement des troubles de l'humeur.
Pitchot, William ; Ansseau, Marc
in Acta Psychiatrica Belgica (2007), 107Detailed reference viewed: 33 (2 ULg)
Therapeutic utilisations of vasopressin and oxytocin in mood disorders.
Scantamburlo, Gabrielle ; Pitchot, William ; Pinto, Emmanuel et al
in Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (2007), 1Detailed reference viewed: 64 (8 ULg)
Le cas clinique du mois. Syndrome malin des neuroleptiques et paralysie generale
; ; Lievens, Isabelle et al
in Revue Médicale de Liège (2006), 61(12), 807-11
Described in 1960 by Jean Delay in relation to the use of haloperidol, neuroleptic malignant syndrome remains relatively rare, and poorly known by the medical profession. The emergence of the atypical ... [more ▼]
Described in 1960 by Jean Delay in relation to the use of haloperidol, neuroleptic malignant syndrome remains relatively rare, and poorly known by the medical profession. The emergence of the atypical antipsychotic agents and preventive measures which have become general in recent years in hospital departments using dopamine receptor antagonists has not altered the prognosis, which remains potentially fatal in approximately a quarter of cases. This article proposes a descriptive summary of this syndrome in terms of clinical and biological diagnostics as well as of evolution, epidemiology, differential diagnosis and treatment. It describes the case of a patient affected by general paralysis having developed a neuroleptic malignant syndrome, thus the hypothesis what the neuroleptic malignant syndrome preferentially arises in subjects having underlying organic or metabolic problems and provides food for thought regarding the main medical and psychiatric overlaps, the use of dopaminergic agents and the behaviour to be adopted when dealing with a patient presenting with inaugural psychiatric symptomatology. [less ▲]Detailed reference viewed: 43 (2 ULg)
Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization
; Ansseau, Marc ; Lemaire, Michelle et al
in Biological Psychiatry (2006), 60(1), 49-57
Background. Amphetamine administration induces stimulation-independent dopainine release in the nucleus accumbens (NAcc) through reverse dopamine transport, a critical neurochemical event involved in its ... [more ▼]
Background. Amphetamine administration induces stimulation-independent dopainine release in the nucleus accumbens (NAcc) through reverse dopamine transport, a critical neurochemical event involved in its psycbostimulant action, and, furthermore decreases stimulation-dependent vesicular dopamine release. These effects may involve possible indirect glutamateigic mechanisms. Methods: We investigated the effiects of nitrous oxide and xenon, which possess antagonistic action at the N-methyl-D-aspartate (NMDA) receptor, on brain slices ex vivo on aniphetamine-induced changes in carrier-mediated and KCI-evoked dopamine release in the NAcc, and in vivo on ampbetamine-induced locomotor sensitization Results: Like the low-affininity NMDA receptor antagonist memantine, but not the prototypical compound MK-801, nitrous oxide and xenon at appropriate concentrations blocked both the increase in carrier-mediated dopamine release and locomotor sensitization produced by amphetamine. Conclusions: In contrast to what has generally been found using prototypical NMDA receptor antagonists, these data regarding the effect qf memantine, nitrous oxide, and xenon support the hypothesis that activation qf certain NMDA receptors (possibly those qf containing the NR1a/NR2D subunit) in the NAcc is involved in the ampbetamine-induced increase in carrier-mediated dopamine release and the development qf behavioral sensitization to amphetamine. Nitrous oxide, xenon, and memantine may be of therapeutic interest for treating drug dependence. [less ▲]Detailed reference viewed: 73 (12 ULg)
Impact of low-frequency transcranial magnetic stimulation on brain automatic information processing - A mismatch negativity study
Laloyaux, Olivier ; Ansseau, Marc ; Hansenne, Michel
in Journal of Psychophysiology (2006), 20(4), 267-275
Repetitive transcranial magnetic stimulation (rTMS) is considered a powerful method for the study of the relationships between cortical activity and-cognitive processes. Previous ERPs studies' that ... [more ▼]
Repetitive transcranial magnetic stimulation (rTMS) is considered a powerful method for the study of the relationships between cortical activity and-cognitive processes. Previous ERPs studies' that focused on P300 response have shown that inhibitory/excitatory effects on prefrontal cortex (PFC), induced by low- and high-frequency rTMS, were able to modulate controlled but not automatic information processing. The present study assessed the impact of inhibition over left and right PFC induced by rTMS on mismatch negativity (MMN), which is known to represent automatic cerebral processes for detecting change. Auditory MMN was recorded in 20 subjects before and after application of left and right PFC 1-Hz rTMS for 15 min. MMN was also recorded before and after a sham-occipital 1-Hz rTMS as control condition. Results showed that 1-Hz rTMS induced no modification to either MMN latency or amplitude. In addition, N100 and P200 components to the frequent tones were not affected by rTMS. These results are consistent with previous findings showing that rTMS; over both PFC is unable to disrupt automatic information processing. However, since two sites were stimulated in the present-study, no definite conclusions about the inability of rTMS to disrupt automatic processing can be made. [less ▲]Detailed reference viewed: 63 (4 ULg)
AVP- and OT-neurophysins response to apomorphine and clonidine in major depression
Scantamburlo, Gabrielle ; ; Pitchot, William et al
in Psychoneuroendocrinology (2005), 30(9), 839-845
A number of studies have reported abnormalities of neurohypophyseal secretions in major depressive disorder. The purpose of the present study was to test the influence of apomorphine and clonidine ... [more ▼]
A number of studies have reported abnormalities of neurohypophyseal secretions in major depressive disorder. The purpose of the present study was to test the influence of apomorphine and clonidine injections on plasma vasopressin (AVP)-neurophysins and oxytocin(OT)-neurophysins levels, as direct index of posterior pituitary activation in major depression. Apomorphine and clonidine tests were carried out in 25 medication-free depressive patients and 25 age and gender-matched healthy controls. Blood for neurophysins analysis was drawn by venipuncture at t0, t+20, t+40, t+60 and t+120. Baseline AVP-neurophysins concentrations were significantly tower in depressives (0.12 +/- 0.14 ng/ml) than in healthy subjects (0.24 +/- 2.15 ng/ml) (p < 0.04). The response to apomorphine test revealed a significant reduced response at 20 (p=0.01), 40 (p=0.007) and 60 (p=0.02) and 120 (p=0.02) min. Following clonidine test, post hoc tests also revealed a significant decrease at 0 (p=0.04), 20 (p=0.01), 40 (p=0.007) and 60 (p=0.02) and 120 (p=0.006) min. Concerning OT-neurophysins, no significant differences were found between depressed and controls in response to clonidine or apomorphine injections. Following clonidine and apomorphine, major depressives exhibited a significantly lower peak GH response than controls. The study supports partially the hypothesis of a reduced vasopressinergic activity in depression. Moreover, we did not find any influence of acute apomorphine or clonidine injections on vasopressin-neurophysin or oxytocin-neurophysin in depressive patients. (c) 2005 Elsevier Ltd. All rights reserved. [less ▲]Detailed reference viewed: 8 (0 ULg)
Neurophysins response to apomorphine and clonidine in major depression
Scantamburlo, Gabrielle ; Ansseau, Marc ; Legros, Jean-Jacques
in European Neuropsychopharmacology (2005, March), 15(Suppl. 1), 77-78Detailed reference viewed: 5 (4 ULg)
Obsessive-compulsive personality disorder: Response to pharmacological treatment.
in Maj, M.; Akiskal, H. S.; Mezzich, J. E. (Eds.) et al Personality Disorders (2005)Detailed reference viewed: 19 (1 ULg)
Therapeutic application of right prefrontal low repetitive transcranial magnetic stimulation on depressed patients
; Reggers, Jean ; Pinto, Emmanuel et al
in European Neuropsychopharmacology (2004, October), 14(Suppl. 3), 226Detailed reference viewed: 18 (5 ULg)
Neurohypophyseal response to apomorphine and clonidine stimulation in major depression
Scantamburlo, Gabrielle ; ; Pitchot, William et al
in European Neuropsychopharmacology (2004, October), 14(Suppl. 3), 291-292Detailed reference viewed: 8 (2 ULg)
Personality profile and drug of choice; a multivariate analysis using Cloninger's TCI on heroin addicts, alcoholics, and a random population group.
; ; et al
in Drug and Alcohol Dependence (2004), 73(2), 175-82
As personality may predispose, precipitate or perpetuate substance abuse and/or dependence, and as it is considered to remain stable across the years in a given subject, potential links with the drug of ... [more ▼]
As personality may predispose, precipitate or perpetuate substance abuse and/or dependence, and as it is considered to remain stable across the years in a given subject, potential links with the drug of choice may help screen future patients before drug consumption. The present study compared three groups: 42 patients with heroin dependence (mean age: 31.2; standard deviation (SD): 5.5; 10 females), 37 patients with alcohol dependence (mean age 44.2; SD: 9.1; 9 females) and 83 subjects from a random population sample (mean age: 38.8; SD: 6.9; 20 females). Personality was measured by Cloninger's Temperament and Character Inventory (TCI). Pillai's MANCOVA with age as a covariate and gender as a cofactor was highly significant. Univariate ANOVA analyses using TCI dimensions as dependent variable showed most variables to vary in parallel for the two patient groups in comparison with controls. Post-hoc tests showed heroin patients to score higher in Novelty-Seeking and Self-Directedness than alcohol patients. Sub-dimensions Exploratory Excitability, Fear of the Uncertain, Responsibility, Congruent Second Nature and Transpersonal Identification were also significantly different in the two patient samples. Logistic regression showed Exploratory Excitability to segregate up to 76% of heroin patients from alcohol patients. In conclusion, personality profiles were linked to some preferential choice of drug and personality screening might be tested in preventive strategies. [less ▲]Detailed reference viewed: 66 (11 ULg)